Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | J. Kay Noel, Kazunori Iwata, Shinsuke Ooike, Kunio Sugahara, Hideo Nakamura, Masanori Daibata | ||||||||||||
Title | Abstract C244: Development of the BET bromodomain inhibitor OTX015. | ||||||||||||
|
|||||||||||||
URL | http://mct.aacrjournals.org/content/12/11_Supplement/C244.short | ||||||||||||
Abstract Text | Mol Cancer Ther November 2013 12:C244; doi:10.1158/1535-7163.TARG-13-C244 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Birabresib | Birabresib | 3 | 3 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Birabresib | Y-803|MK-8628|OTX015|OTX-015 | BET Inhibitor (Pan) 32 | Birabresib (OTX015) is an inhibitor of the BET bromodomain proteins BRD3, BRD4, and BRD5, which inhibits interaction with acetylated histone H4, potentially resulting in decreased tumor cell proliferation (Mol Cancer Ther Nov 2013 12:C244, PMID: 29733771, PMID: 31204545). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|